The diagnostic value of cytoplasmic expression of the transcription factor Oct4 in neuroendocrine tumors ; Диагностическое значение цитоплазматической экспрессии фактора транскрипции Oct4 в нейроэндокринных опухолях

Συγγραφείς: Gurevich L.E., Ilovayskaya I.A., Lugovskaya A.Y., Markarova E.V., Kogoniya L.M., Setdikova G.R., Tyurina V.M., Yakovenko I.P.

Συνεισφορές: 1

Πηγή: Almanac of Clinical Medicine; Vol 53, No 4 (2025); 169-179 ; Альманах клинической медицины; Vol 53, No 4 (2025); 169-179 ; 2587-9294 ; 2072-0505

Θεματικοί όροι: Oct4, neuroendocrine tumors, pheochromocytoma, paraganglioma, functional type, malignant potential, нейроэндокринные опухоли, феохромоцитома, параганглиома, функциональный тип, злокачественный потенциал

Περιγραφή αρχείου: application/pdf

Relation: https://almclinmed.ru/jour/article/view/17541/1753; https://almclinmed.ru/jour/article/view/17541/1754; https://almclinmed.ru/jour/article/downloadSuppFile/17541/160715; https://almclinmed.ru/jour/article/downloadSuppFile/17541/160716; https://almclinmed.ru/jour/article/downloadSuppFile/17541/160717; https://almclinmed.ru/jour/article/downloadSuppFile/17541/160718; https://almclinmed.ru/jour/article/downloadSuppFile/17541/160719; https://almclinmed.ru/jour/article/downloadSuppFile/17541/160720; https://almclinmed.ru/jour/article/downloadSuppFile/17541/160721; https://almclinmed.ru/jour/article/downloadSuppFile/17541/160722; https://almclinmed.ru/jour/article/downloadSuppFile/17541/160723; https://almclinmed.ru/jour/article/downloadSuppFile/17541/160724; https://almclinmed.ru/jour/article/view/17541

Διαθεσιμότητα: https://almclinmed.ru/jour/article/view/17541
https://doi.org/10.18786/2072-0505-2025-53-017

Serum concentrations of chromogranin A, serotonin and natriuretic peptide are decreased in patients with neuroendocrine tumors with overweight and obesity compared to healthy donors ; Сывороточные концентрации хромогранина А, серотонина и натрийуретического пептида снижены у больных нейроэндокринными опухолями с избыточной массой тела и ожирением в сравнении со здоровыми донорами

Συγγραφείς: Timofeev Y.S., Lyubimova N.V., Drapkina O.M.

Συνεισφορές: 1

Πηγή: Almanac of Clinical Medicine; Vol 52, No 3 (2024); 162-169 ; Альманах клинической медицины; Vol 52, No 3 (2024); 162-169 ; 2587-9294 ; 2072-0505

Θεματικοί όροι: neuroendocrine tumors, obesity, body mass index, chromogranin A, serotonin, NT-proBNP, нейроэндокринные опухоли, ожирение, индекс массы тела, хромогранин А, серотонин

Περιγραφή αρχείου: application/pdf

Relation: https://almclinmed.ru/jour/article/view/17254/1666; https://almclinmed.ru/jour/article/view/17254/1679; https://almclinmed.ru/jour/article/downloadSuppFile/17254/159928; https://almclinmed.ru/jour/article/downloadSuppFile/17254/159929; https://almclinmed.ru/jour/article/downloadSuppFile/17254/160037; https://almclinmed.ru/jour/article/downloadSuppFile/17254/160038; https://almclinmed.ru/jour/article/downloadSuppFile/17254/160039; https://almclinmed.ru/jour/article/downloadSuppFile/17254/160040; https://almclinmed.ru/jour/article/view/17254

Διαθεσιμότητα: https://almclinmed.ru/jour/article/view/17254
https://doi.org/10.18786/2072-0505-2024-52-019

On the history and some characteristics of neuroendocrine tumors of the gastrointestinal tract. Review. Part 1

Συγγραφείς: S. Rybakov

Πηγή: Clinical Endocrinology and Endocrine Surgery; No. 2 (2021); 60-72
Clinical Endocrinology and Endocrine Surgery; № 2 (2021); 60-72

Θεματικοί όροι: нейроэндокринные опухоли, желудочно-кишечный тракт, инсулинома, глюкагонома, нейроендокринні пухлини, шлунково-кишковий тракт, інсулінома, neuroendocrine tumors, gastrointestinal tract, insulinoma, glucagonoma, 3. Good health

Περιγραφή αρχείου: application/pdf

Σύνδεσμος πρόσβασης: http://jcees.endocenter.kiev.ua/article/download/235579/233949
http://jcees.endocenter.kiev.ua/article/view/235579

Пептидрецепторна радіонуклідна терапія гастроентеропанкреатичних нейроендокринних пухлин: профіль ефективності та безпечності використання, критерії вибору методу

Συγγραφείς: B.I. Zadorizhnyi, B.I. Zadorizhnyi, Hanchenko, Ya.A.

Πηγή: Practical oncology; Том 2, № 4 (2019); 20-25
Практическая онкология-Praktična onkologìâ; Том 2, № 4 (2019); 20-25
Практична онкологія-Praktična onkologìâ; Том 2, № 4 (2019); 20-25

Θεματικοί όροι: gastroenteropancreatic neuroendocrine tumours, peptide receptor radionuclide therapy, 90Y-Dotatoc, 177Lu-DOTATATE, radiolabeled receptors, NETTER-1, гастроэнтеропанкреатические нейроэндокринные опухоли, пептидрецепторная радионуклидная терапия, радиоактивно меченные рецепторы, гастроентеропанкреатичні нейроендокринні пухлини, пептидрецепторна радіонуклідна терапія, радіоактивно мічені рецептори, 3. Good health

Περιγραφή αρχείου: application/pdf

Σύνδεσμος πρόσβασης: http://oncology.zaslavsky.com.ua/article/download/195183/197104
http://oncology.zaslavsky.com.ua/article/view/195183

Radioligand therapy with drugs based on radionuclide 225Aс: experience of A.M.Granov Russian scientific center of radiology and surgical technologies ; Радиолигандная терапия препаратами на основе радионуклида 225Ас: опыт Российского научного центра радиологии и хирургических технологий имени академика А.М.Гранова

Συγγραφείς: D. N. Maystrenko, A. A. Stanzhevskii, D. A. Vazhenina, M. V. Odintsova, S. A. Popov, V. B. Nomokonova, L. A. Chipiga, K. A. Saprykin, A. V. Gromov, S. K. Vasiliev, Д. Н. Майстренко, А. А. Станжевский, Д. А. Важенина, М. В. Одинцова, С. А. Попов, В. Б. Номоконова, Л. А. Чипига, К. А. Сапрыкин, А. В. Громов, С. К. Васильев

Πηγή: Diagnostic radiology and radiotherapy; Том 13, № 4 (2022); 86-94 ; Лучевая диагностика и терапия; Том 13, № 4 (2022); 86-94 ; 2079-5343

Θεματικοί όροι: нейроэндокринные опухоли, oncology, theranostics, prostate cancer, neuroendocrine tumors, онкология, тераностика, рак предстательной железы

Περιγραφή αρχείου: application/pdf

Relation: https://radiag.bmoc-spb.ru/jour/article/view/807/577; Morgenstern A. An Overview of Targeted Alpha Therapy with 225 Actinium and 213 Bismuth // Current Radiopharmaceuticals. 2018. Vol. 11, No. 3, pp. 200–208. doi:10.2174/1874471011666180502104524.; Kratochwil C. Targeted a-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225 Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding // The Journal of Nuclear Medicine. 2017. Vol. 58, No. 10, pp. 1624–1631. doi:10.2967/jnumed.117.191395.; Özgüven S. Physiological Biodistribution of 68 Ga-DOTA-TATE in Normal Subjects // Molecular Imaging And Radionuclide Therapy. 2021. Vol. 30, No. 1, pp. 39–46. doi:10.4274/mirt.galenos.2021.37268.; Hooijman E. Development of [ 225 Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC // Pharmaceutic. 2021. Vol. 13, No. 5. Р. 715. doi:10.3390/pharmaceutics13050715.; Birindelli G. In silico study on radiobiological efficacy of Ac-225 and Lu-177 for PSMA-guided radiotherapy // 43 rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society (USA, New York, 01–05 November 2021 year). New York, 2021. Р. 4497–4500. doi:10.1109/EMBC46164.2021.9630297.; Lunger L. Narrative review: prostate-specific membrane antigen-radioligand therapy in metastatic castration-resistant prostate cancer // Translational Andrology and Urology. 2021. Vol. 10, No. 10. Р. 3963–3971. doi:10.21037/tau-20-1135.4.; Stefe M. Intra-therapeutic dosimetry of [ 177 Lu] Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome // European Journal of Nuclear Medicine and Molecular Imaging. 2022. Vol. 49, No. 2. Р. 460–469. doi:10.1007/s00259-021-05471-4.; Шкала ECOG. https://onconet.online/lib/4/diagn/207 (дата обращения 18.11.2022).; Критерии PERCIST. https://recist.eortc.org/recist-1–1-2 (дата обращения 18.11.2022).; Радионуклидная диагностика для практических врачей / под ред. Ю.Б.Лишманова, В.И.Чернова, Новосибирск: STT, 2004. 387 с. ISBN 5-93629-166-9.; Афанасьев В.В. Слюнные железы. Болезни и травмы: руководство для врачей. Москва: ГЭОТАР-Медиа, 2012. 296 с. ISBN 978-5-9704-2066-9.

Διαθεσιμότητα: https://radiag.bmoc-spb.ru/jour/article/view/807
https://doi.org/10.22328/2079-5343-2022-13-4-86-94

Endoscopic radiofrequency ablation under the control of ultrasonography as a new method of treatment of neuroendocrine pancreatic tumors and analgesia option for locally advanced forms of pancreatic cancer. First experience in Russia ; Эндоскопическая радиочастотная абляция под контролем ультрасонографии как новый метод лечения нейроэндокринных опухолей поджелудочной железы и вариант анальгезии при местно-распространенных формах рака поджелудочной железы. Первый опыт в России

Συγγραφείς: V. V. Lozovaya, O. A. Malikhova, A. S. Vodoleev, O. A. Gusarova, A. O. Tumanyan, A. G. Malikhov, В. В. Лозовая, О. А. Малихова, А. С. Водолеев, О. А. Гусарова, А. О. Туманян, А. Г. Малихов

Πηγή: Surgery and Oncology; Том 13, № 3 (2023); 11-20 ; Хирургия и онкология; Том 13, № 3 (2023); 11-20 ; 2949-5857

Θεματικοί όροι: анальгезия, endosonographic study, pancreatic nET, pancreatic cancer, pancreatic adenocarcinoma, pain syndrome, analgesia, эндосонографическое исследование, нейроэндокринные опухоли поджелудочной железы, рак поджелудочной железы, аденокарцинома поджелудочной железы, болевой синдром

Περιγραφή αρχείου: application/pdf

Relation: https://www.onco-surgery.info/jour/article/view/641/434; Fitzgerald T.L., Hickner Z.J., Schmitz M. et al. Changing incidence of pancreatic neoplasms: a 16-year review of statewide tumor registry. Pancreas 2008;37:134–8. DOI:10.1097/MPA.0b013e318163a329; Jilesen A.P., van Eijck C.H., Busch O.R. et al. Postoperative Outcomes of Enucleation and Standard Resections in Patients with a Pancreatic Neuroendocrine Tumor. World J Surg 2016;40:715–28. DOI:10.1007/s00268-015-3341-9; Mehrabi A., Fischer L., Hafezi M. et al. A systematic review of localization, surgical treatment options, and outcome of insulinoma. Pancreas 2014;43(5):675–86. DOI:10.1097/MPA.0000000000000110; Lee D.W., Kim M.K., Kim H.C. Diagnosis of pancreatic neuroendo crine tumors. Clin Endosc 2017;50:537–45. DOI:10.5946/ce.2017.131; Choi J.H., Seo D.W., Song T.J. et al. Endoscopic ultrasound-guided radiofrequency ablation for management of benign solid pancreatic tumors. Endoscopy 2018;50(11):1099–104. DOI:10.1055/a-0583-8387; Oleinikov K., Dancour A., Epshtein J. et al. Endoscopic ultrasound guided radiofrequency ablation: a new therapeutic approach for pancreatic neuroendocrine tumors. J Clin Endocrinol Metab 2019;104:2637–47. DOI:10.1210/jc.2019-00282; Houmani Z.S., Noureddine M.S. EUS-guided celiac plexus radiofrequency ablation using a novel device. VideoGIE 2020;5(9):395-6. DOI:10.1016/j.vgie.2020.04.022; Lakhtakia S., Seo D.W. Endoscopic ultrasonography-guided tumor ablation. Dig Endosc 2017;29(4):486–94. DOI:10.1111/den.12833; Taewoong medical USA: URL: https://taewoongusa.com/products/viva-combo-rf-generator-system/; Goldberg S.N., Mallery S., Gazelle G.S. et al. EUS-guided radiofrequency ablation in the pancreas: results in a porcine model. Gastrointest Endosc 1999;50(3):392–401. DOI:10.1053/ge.1999.v50.98847; Carrara S., Arcidiacono P.G., Albarello L. et al. Endoscopic ultrasound-guided application of a new hybrid cryotherm probe in porcine pancreas: a preliminary study. Endoscopy 2008;40(4):321–6. DOI:10.1055/s-2007-995595; Kim H.J., Seo D.W., Hassanuddin A. et al. EUS-guided radiofrequency ablation of the porcine pancreas. Gastrointest Endosc 2012;76(5):1039–43. DOI:10.1016/j.gie.2012.07.015; Rossi S., Ravetta V., Rosa L. et al. Repeated radiofrequency ablation for management of patients with cirrhosis with small hepatocellular carcinomas: a long-term cohort study. Hepatology 2011;53(1):136–47. DOI:10.1002/hep.23965; Rossi S., Dore R., Cascina A. et al. Percutaneous computed tomography-guided radiofrequency thermal ablation of small unresectable lung tumours. Eur Respir J 2006; 27(3):556–63. DOI:10.1183/09031936.06.00052905; Atwell T.D., Schmit G.D., Boorjian S.A. et al. Percutaneous ablation of renal masses measuring 3.0 cm and smaller: comparative local control and complications after radiofrequency ablation and cryoablation. AJR Am J Roentgenol 2013;200(2):461–6. DOI:10.2214/AJR.12.8618; Mohan H., Nicholson P., Winter D.C. et al. Radiofrequency ablation for neuroendocrine liver metastases: a systematic review. J Vasc Interv Radiol 2015;26(7):935–42. DOI:10.1016/j.jvir.2014.12.009; Elias D., Baton O., Sideris L. et al. Necrotizing pancreatitis after radiofrequency destruction of pancreatic tumours. Eur J Surg Oncol 2004;30(1):85–7. DOI:10.1016/j.ejso.2003.10.013; Girelli R., Frigerio I., Salvia R. et al. Feasibility and safety of radiofrequency ablation for locally advanced pancreatic cancer. Br J Surg 2010;97(2):22–5. DOI:10.1002/bjs.6800; Khoury T., Sbeit W., Napoléon B. Endoscopic ultrasound guided radiofrequency ablation for pancreatic tumors: A critical review focusing on safety, efficacy and controversies. World J Gastroenterol 2023;29(1):157–70. DOI:10.3748/wjg.v29.i1.157; Rossi S., Viera F.T., Ghittoni G. et al. Radiofrequency ablation of pancreatic neuroendocrine tumors: a pilot study of feasibility, efficacy, and safety. Pancreas 2014;43(6):938–45. DOI:10.1097/MPA.0000000000000133; Armellini E., Crino` S.F., Ballare` M. et al. Endoscopic ultrasound-guided radiofrequency ablation of a pancreatic neuroendocrine tumor. Endoscopy 2015;47(S 01):E600–1. DOI:10.1055/s-0034-1393677; Pai M., Habib N., Senturk H. et al. Endoscopic ultrasound guided radiofrequency ablation, for pancreatic cystic neoplasms and neuroendocrine tumors. World J Gastrointest Surg 2015;7(4):52–9. DOI:10.4240/wjgs.v7.i4.52; Lakhtakia S., Ramchandani M., Galasso D. et al. EUS-guided radiofrequency ablation for management of pancreatic insulinoma by using a novel needle electrode (with videos). Gastrointest Endosc 2016;83(1):234–9. DOI:10.1016/j.gie.2015.08.085; Barthet M., Giovannini M., Lesavre N. et al. Endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine tumors and pancreatic cystic neoplasms: a prospective multicenter study [published online ahead of print 22 January 2019]. Endoscopy 2019;51(9):836–42. DOI:10.1055/a-0824-7067; Bang J.Y., Sutton B., Hawes R.H., Varadarajulu S. EUS-guided celiac ganglion radiofrequency ablation versus celiac plexus neurolysis for palliation of pain in pancreatic cancer: a randomized controlled trial (with videos). Gastrointest Endosc 2019;89(1):58–66. DOI:10.1016/j.gie.2018.08.005

Διαθεσιμότητα: https://www.onco-surgery.info/jour/article/view/641
https://doi.org/10.17650/2949-5857-2023-13-3-11-20

Endoscopic differential diagnosis of the gastritis-like form of primary non-Hodgkin’s lymphomas and neuroendocrine tumors of the stomach ; Эндоскопическая дифференциальная диагностика гастритоподобной формы первичных неходжкинских лимфом и нейроэндокринных опухолей желудка

Συγγραφείς: V. V. Lozovaya, O. A. Malikhova, A. O. Tumanyan, A. G. Malikhov, O. A. Gusarova, В. В. Лозовая, О. А. Малихова, А. О. Туманян, А. Г. Малихов, О. А. Гусарова

Πηγή: Surgery and Oncology; Том 13, № 2 (2023); 27-37 ; Хирургия и онкология; Том 13, № 2 (2023); 27-37 ; 2949-5857

Θεματικοί όροι: эндоскопическая диагностика, neuroendocrine tumors of the stomach, MALT-lymphoma, gastritis-like form of primary NHL of the stomach, endoscopic diagnostics, нейроэндокринные опухоли желудка, MALT-лимфома, гастритоподобная форма первичных НХЛ желудка

Περιγραφή αρχείου: application/pdf

Relation: https://www.onco-surgery.info/jour/article/view/603/420; Bestari M.B., Palungkun I.G., Hernowo B.S. et al. Low-Stage Gastric MALT Lymphoma Causing Life-Threatening Upper Gastrointestinal Bleeding. Case Rep Gastroenterol 2019;13(3):376–84. DOI:10.1159/000502795; Swedlow S.H., Campo E., Harris N.L. et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer, 2008.; Baele M., Pasmans F., Flahou B. et al. Non-Helicobacter pylori Helicobacters detected in the stomach of humans comprise several naturally occurring Helicobacter species in animals. FEMS Immunol Med Microbiol 2009;55:306–13. DOI:10.1111/j.1574-695X.2009.00535.x; Achyut B.R., Moorchung N., Srivastava A.N. et al. Risk of lymphoid follicle development in patients with chronic antral gastritis: role of endoscopic features, histopathological parameters, CagA status and interleukin-1 gene polymorphisms. Inflamm Res 2008;57:51–6. DOI:10.1007/s00011-007-7033-2; Малихова О.А. Современная стратегия комплексной эндоскопической диагностики и мониторинг неходжкинских лимфом желудка: дисс. докт. мед. наук. М., 2010. 291 с.; Ивашкин В.Т., Маев И.В., Лапина Т.Л. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и ассоциации «Эндоскопическое общество РЭНДО» по диа гностике и лечению гастрита, дуоденита. Российский журнал гастроэнтерологии, гепатологии, колопроктологии 2021;31(4):70–99. DOI:10.22416/1382-4376-202131-4-70-99; Filip P.V., Cuciureanu D., Diaconu L.D. et al. MALT lymphoma: epidemiology, clinical diagnosis and treatment. J Med Life 2018;11(3):187–93. DOI:10.25122/jml-2018-0035; Ruskoné-Fourmestraux A., Fischbach W., Aleman B.M. et al. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 2011;60:747–58. DOI:10.1136/gut.2010.224949; Zucca E., Copie-Bergman C., Ricardi U. et al. Gastric marginal zone lymphoma of MALT type: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(6): 144–8. DOI:10.1093/annonc/mdt343; Nagtegaal I.D., Odze R.D., Klimstra D. et al. WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020;76(2):182–8. DOI. 10.1111/his.13975; The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc 2003;58:810–43. DOI:10.1016/s00165107(03)02159-x; Нейроэндокринные опухоли. Общие принципы диагностики и лечения: практическое руководство / Под ред. проф. В.А. Горбуновой. М.: ГЭОТАР-Медиа, 2021. 600 с. DOI:10.33029/9704-5997-3-NEU-2021-1-600; Chin J.L., O’Toole D. Diagnosis and Management of Upper Gastrointestinal Neuroendocrine Tumors. Clin Endosc 2017;50(6):520–9. DOI:10.5946/ce.2017.181; Chung C.S., Tsai C.L., Chu Y.Y. et al. Clinical features and outcomes of gastric neuroendocrine tumors after endoscopic diagnosis and treatment: A Digestive Endoscopy Society of Tawian (DEST). Medicine (Baltimore) 2018;97(38):e12101. DOI:10.1097/MD.0000000000012101; Гордеев С.С., Магаррамова З.Н., Мышляков В.С. и др. Редкие злокачественные новообразования в практике онкопроктолога: ретроспективный анализ опыта клиники за 20 лет. Поволжский онкологический вестник 2023;13(4):31–7. DOI:10.32000/2078-1466-2022-4-31-37; Гордеев С.С. Роль химиолучевой терапии в лечении нейроэндокринного рака прямой кишки: серия клинических наблюдений. Сибирский онкологический журнал 2022;21(4):90–7.

Διαθεσιμότητα: https://www.onco-surgery.info/jour/article/view/603
https://doi.org/10.17650/2686-9594-2023-13-2-27-37

Biochemical factors in the blood serum of neuroendocrine tumor patients with carcinoid syndrome ; Биохимические показатели в сыворотке крови больных нейроэндокринными опухолями с карциноидным синдромом

Συγγραφείς: N. V. Lyubimova, Yu. S. Timofeev, A. V. Lebedeva, A. V. Artamonova, I. S. Stilidi, N. E. Kushlinskii, Н. В. Любимова, Ю. С. Тимофеев, А. В. Лебедева, Е. В. Артамонова, И. С. Стилиди, Н. Е. Кушлинский

Πηγή: Advances in Molecular Oncology; Том 9, № 4 (2022); 71‑77 ; Успехи молекулярной онкологии; Том 9, № 4 (2022); 71‑77 ; 2413-3787 ; 2313-805X ; 10.17650/2313-805X-2022-9-4

Θεματικοί όροι: нейроэндокринные опухоли, serotonin, pro-brain natriuretic peptide, platelet-derived growth factor, neuroendocrine tumors, серотонин, мозговой натрийуретический пропетид, тромбоцитарный фактор роста

Περιγραφή αρχείου: application/pdf

Relation: https://umo.abvpress.ru/jour/article/view/478/282; Aluri V., Dilon J.S. Biochemical testing in neuroendocrine tumors. Endocrinol Metab Clin North Am 2017;46(3):669–77. DOI:10.1016/j.ecl.2017.04.004; Hofland J., Kaltsas G., de Herder W.W. Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms. Endocr Rev 2020;41(2):371–403. DOI:10.1210/endrev/bnz004; Eriksson B., Oberg K., Stridsberg M. Tumor markers in neuroendocrine tumors. Digestion 2000;62(1):33–8. DOI:10.1159/000051853; De Herder W.W. Biochemistry of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007;21(1):33–41. DOI:10.1016/j.beem.2006.12.002; Vinik A.I., Silva M.P., Woltering E.A. et al. Biochemical testing for neuroendocrine tumors. Pancreas 2009;38(8):876–89. DOI:10.1097/MPA.0b013e3181bc0e77; Fanciulli G., Ruggeri R.M., Grossrubatscher E. et al. Serotonin pathway in carcinoid syndrome: сlinical, diagnostic, prognostic and therapeutic implications. Rev Endocr Metab Disord 2020;21(4):599–12. DOI:10.1007/s11154-020-09547-8; Jian B., Xu J., Connolly J. et al. Serotonin mechanisms in heart valve disease I: serotonin-induced up-regulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells. Am J Pathol 2002;161(6):2111–21. DOI:10.1016/s0002-9440(10)64489-6; Lesurtel M., Soll C., Graf R., Clavien P.A. Role of serotonin in the hepato- gastrointestinal tract: an old molecule for new perspectives. Cell Mol Life Sci 2008;65(6):940–52. DOI:10.1007/s00018-007-7377-3; Hayes A.R., Davar J., Caplin M.E. Carcinoid heart disease: a review. Endocrinol Metab Clin North Am 2018;47(3):671–82. DOI:10.1016/j.ecl.2018.04.012; Bhattacharyya S., Toumpanakis C., Chilkunda D. et al. Risk factors for the development and progression of carcinoid heart disease. Am J Cardiol 2011;107(8):1221–6. DOI:10.1016/j.amjcard.2010. 12.025; Grozinsky-Glasberg S., Grossman A.B., Gross D.J. Carcinoid heart disease: from pathophysiology to treatment – something in the way it moves. Neuroendocrinology 2015;101(4):263–73. DOI:10.1159/000381930; Jin C., Sharma A.N., Thevakumar B. et al. Carcinoid heart disease: pathophysiology, pathology, clinical manifestations, and management. Cardiology 2021;146(1):65–73. DOI:10.1159/000507847; Kong P., Christia P., Frangogiannis N.G. The pathogenesis of cardiac fibrosis. Cell Mol Life Sci 2014;71(4):549–74. DOI:10.1007/s00018-013-1349-6; Laskaratos F.M., Rombouts K., Caplin M. et al. Neuroendocrine tumors and fibrosis: an unsolved mystery? Cancer 2017;123(24):4770–90. DOI:10.1002/cncr.31079; Fredriksson L., Li H., Eriksson U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev 2004;15(4):197–204. DOI:10.1016/j.cytogfr.2004.03.007; Klinkhammer B.M., Floege J., Boor P. PDGF in organ fibrosis. Mol Aspects Med 2018;62:44–62. DOI:10.1016/j.mam.2017.11.008; Chaudhry A., Papanicolaou V., Oberg K. et al. Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system. Cancer Res 1992;52(4):1006–12.; Oberg K. Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2011;18(1):17–25. DOI:10.1530/ERC-10-0280; Jun E., Kim S.C., Song K.B. et al. Diagnostic value of chromogranin A in pancreatic neuroendocrine tumors depends on tumor size: a prospective observational study from a single institute. Surgery 2017;162(1):120–30. DOI:10.1016/j.surg.2017.01.019; Modlin I.M., Gustafsson B.I., Moss S.F. et al. Chromogranin A – biological function and clinical utility in neuroendocrine tumor disease. Ann Surg Oncol 2010;17(9):2427–43. DOI:10.1245/s10434-010-1006-3; Любимова Н.В., Тимофеев Ю.С., Чурикова Т.К. и др. Значение хромогранина А в диагностике и прогнозе нейроэндокринных опухолей. Медицинский алфавит 2019;17(2):19–22. DOI:10.33667/2078-5631-2019-2-17(392)-19-22; Любимова Н.В., Кушлинский Н.Е. Биохимические маркеры сыворотки крови и мочи при обследовании больных нейроэндокринными опухолями. Альманах клинической медицины 2016;44(4):439–50. DOI:10.18786/2072-0505-2016-44-4-439-450; Любимова Н.В., Тимофеев Ю.С., Чурикова Т.К. и др. Хромогранин А и серотонин в оценке эффективности лечения нейроэндокринных опухолей. Альманах клинической медицины 2019;47(8):685–90. DOI:10.18786/2072-0505-2019-47-054; Korse C.M., Taal B.G., de Groot C.A. et al. Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor. J Clin Oncol 2009;27(26):4293–99. DOI:10.1200/JCO.2008.18.7047; https://umo.abvpress.ru/jour/article/view/478

Διαθεσιμότητα: https://umo.abvpress.ru/jour/article/view/478
https://doi.org/10.17650/2313-805X-2022-9-4-71-77

Targeted treatment with somatostatin analogues: widening horizons of clinical practice ; Таргетное назначение аналогов соматостатина: расширяющиеся горизонты клинической практики

Συγγραφείς: Pronin V.S., Antsiferov M.B., Alexeeva T.M., Pronin E.V.

Συνεισφορές: 1

Πηγή: Almanac of Clinical Medicine; Vol 50, No 3 (2022); 196-204 ; Альманах клинической медицины; Vol 50, No 3 (2022); 196-204 ; 2587-9294 ; 2072-0505

Θεματικοί όροι: somatostatin analogues, drug treatment, acromegaly, neuroendocrine tumors, аналоги соматостатина, медикаментозное лечение, акромегалия, нейроэндокринные опухоли

Περιγραφή αρχείου: application/pdf

Relation: https://almclinmed.ru/jour/article/view/1496/1462; https://almclinmed.ru/jour/article/view/1496/1495; https://almclinmed.ru/jour/article/downloadSuppFile/1496/2425; https://almclinmed.ru/jour/article/downloadSuppFile/1496/3085; https://almclinmed.ru/jour/article/view/1496

Διαθεσιμότητα: https://almclinmed.ru/jour/article/view/1496
https://doi.org/10.18786/2072-0505-2022-50-019

Radiotheranostics of neuroendocrine neoplasms: quo vadis ; Радиотераностика нейроэндокринных неоплазий: quo vadis

Συγγραφείς: Rumyantsev P.O.

Πηγή: Almanac of Clinical Medicine; Vol 49, No 4 (2021); 297-303 ; Альманах клинической медицины; Vol 49, No 4 (2021); 297-303 ; 2587-9294 ; 2072-0505

Θεματικοί όροι: neuroendocrine tumors, radiotheranostics, theranostics, molecular visualization, radiotargeted therapy, нейроэндокринные опухоли, радиотераностика, тераностика, молекулярная визуализация, радиотаргетная терапия

Περιγραφή αρχείου: application/pdf

Relation: https://almclinmed.ru/jour/article/view/1583/1373; https://almclinmed.ru/jour/article/downloadSuppFile/1583/2604; https://almclinmed.ru/jour/article/downloadSuppFile/1583/2605; https://almclinmed.ru/jour/article/downloadSuppFile/1583/2606; https://almclinmed.ru/jour/article/downloadSuppFile/1583/2607; https://almclinmed.ru/jour/article/view/1583

Διαθεσιμότητα: https://almclinmed.ru/jour/article/view/1583
https://doi.org/10.18786/2072-0505-2021-49-048

Predictive value of morphological features and proliferative markers (mitotic index, Ki-67, PHH3) in bronchopulmonary neuroendocrine tumors ; Прогностическая ценность морфологических особенностей и пролиферативных маркеров (митотического индекса, Ki-67, PHH3) в нейроэндокринных опухолях бронхолёгочной локализации ; Прогностична цінність морфологічних особливостей та проліферативних маркерів (мітотичного індексу, Ki-67, PHH3) у нейроендокринних пухлинах бронхолегеневої локалізації

Συγγραφείς: Захарцева, Л. М., Читаєва, Г. Є.

Πηγή: Pathologia; Vol. 18 No. 3 (2021): Pathologia; 254 - 262 ; Патология; Том 18 № 3 (2021): Патология; 254 - 262 ; Патологія; Том 18 № 3 (2021): Патологія; 254 - 262 ; 2310-1237 ; 2306-8027

Θεματικοί όροι: нейроендокринні пухлини легень, морфологія, імуногістохімія, мітотичний індекс, некроз, Ki-67, PHH3, метастази, показники виживаності, нейроэндокринные опухоли лёгких, морфология, иммуногистохимия, митотический индекс, метастазы, показатели выживаемости, lung neuroendocrine tumor, morphology, mitotic index, necrosis, metastases, survival rates, immunohistochemistry

Περιγραφή αρχείου: application/pdf

Relation: http://pat.zsmu.edu.ua/article/view/239530/246788; http://pat.zsmu.edu.ua/article/view/239530

Διαθεσιμότητα: http://pat.zsmu.edu.ua/article/view/239530

НЭО G3 — новая подгруппа, новые подходы

Συγγραφείς: Е. В. Евдокимова, Е. В. Артамонова, В. В. Делекторская, Г. Ю. Чемерис

Πηγή: Malignant tumours; Том 11, № 3s1 (2021); 16-18 ; Злокачественные опухоли; Том 11, № 3s1 (2021); 16-18 ; 2587-6813 ; 2224-5057

Θεματικοί όροι: нейроэндокринные опухоли, НЭО Grade 3, высокодифференцированные, высокозлокачественные

Περιγραφή αρχείου: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/846/594; Pavel M, O’Toole D, Costa F, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 2016;103:172– 85.; Sorbye, H., Welin, S ., Langer, S . W., Vestermark, L . W., Holt, N., Osterlund, P., Knigge, U. (2012). Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma ( WHO G3): The NORDIC NEC study. Annals of Oncology, 24 (1), 152–160; Shibuya, H., Hijioka, S., Sakamoto, Y., Ito, T., Ueda, K., Komoto, I., Okusaka, T. (2018). Multi-center clinical evaluation of streptozocinbased chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy. Cancer Chemotherapy and Pharmacology.; Dilz, L.-M., Denecke, T., Steffen, I. G., Prasad, V., von Weikersthal, L. F., Pape, U.-F., Pavel, M. (2015). Streptozocin / 5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours. European Journal of Cancer, 51 (10), 1253–1262; Ono, H., Kudo, A ., Akahoshi, K., Ogura, T., Ogawa, K., Ban, D., Tanabe, M. (2019). Combination of weekly streptozocin and oral S-1 treatment for patients of unresectable or metastatic pancreatic neuroendocrine neoplasms. Journal of Cancer Research and Clinical Oncology; Clewemar Antonodimitrakis , P.,Sundin, A, Wassberg, C., Granberg, D., Skogseid, B., & Eriksson, B. (2015). Streptozocin and 5 - Fluorouracil for the Treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity. Neuroendocrinology, 103 (3– 4), 345–353; Krug, S., Boch, M., Daniel, H., Nimphius, W., Müller, D., Michl, P., Gress, T. M. (2015). Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms — Predictive and Prognostic Markers for Treatment Stratification. PLOS ONE, 10 (12), e0143822.; Apostolidis , L .;DalBuono, A .; Merola, E.; Jann, H .; Jäger, D.; Wiedenmann, B.; Winkler, E. C.; Pavel, M. Multicenter Analysis of Treatment Outcomes for Systemic Therapy in Well Differentiated Grade 3 Neuroendocrine Tumors (NET G3). Cancers2021,13,1936; David L. Chan, Emily k. Bergsland, Jennifer A. Chan, Rujuta Gadgil, Thorvardur R. Halfdanarson, Kathleen Hornbacker, Virginia Kelly, Pamela L. Kunz, Patrick W. Mcgarrah, Nitya P. Raj, Diane L. Reidy, Alia Thawer, Julia Whitman, Linda Wu, Christoph Becker, Simron Singh. Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review. The Oncologist 2021;25:1– 6; Yerci O, Sehitoglu I, Ugras N, Cubukcu E, Yuce S, Bedir R , Cure E. Somatostatin receptor 2 and 5 expressionsin gastroenteropancreatic neuroendocrine tumors in Turkey. Asian Pac J Cancer Prev. 2015;16 (10):4377– 81.; Kanakis G, Grimelius L, Spathis A, Tringidou R, Rassidakis GZ, Öberg K, Kaltsas G, Tsolakis AV. Expression of Somatostatin Receptors 1–5 and Dopamine Receptor 2 in Lung Carcinoids: Implications for a Therapeutic Role. Neuroendocrinology. 2015;101 (3):211–22.; Suk-young Lee, Yoon Ji Choi1, Won Jin Chang, Sang Won Shin, Yeul Hong Kim, Seung Tae Kim. The role of chemotherapy and / or octreotide in patients with metastatic gastroenteropancreatic and hepatobiliary neuroendocrine carcinoma. Gastrointest Oncol 2014;5 (6):457– 462; Li J, Lu M, Lu Z, Li Z, Liu Y, Yang L, Li J, Zhang X, Zhou J, Wang X, Gong J, Gao J, Li Y, Shen L. Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study. Oncotarget. 2017 Apr 11;8 (15):25669 - 25678.; https://www.malignanttumors.org/jour/article/view/846

Διαθεσιμότητα: https://www.malignanttumors.org/jour/article/view/846
https://doi.org/10.18027/2224-5057-2021-11-3s1-16-18

Neuroendocrine Breast Cancer. Clinical Observation. Personalized Approach

Συγγραφείς: Sh. Kh. Gantsev, G. Schaller, K. Sh. Gantsev, A. N. Plikhta, Sh. R. Kzyrgalin, R. A. Rustamkhanov

Πηγή: Креативная хирургия и онкология, Vol 11, Iss 2, Pp 144-148 (2021)

Θεματικοί όροι: нейроэндокринные опухоли, рак груди, молочная железа, синаптофизин, хромогранин а, персонифицированная лекарственная терапия, лучевая терапия, Surgery, RD1-811, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

Relation: https://www.surgonco.ru/jour/article/view/584; https://doaj.org/toc/2307-0501; https://doaj.org/toc/2076-3093; https://doaj.org/article/87cd978da44f426393e9be29abe216f4

Διαθεσιμότητα: https://doi.org/10.24060/2076-3093-2021-11-2-144-148
https://doaj.org/article/87cd978da44f426393e9be29abe216f4

On the history and some characteristics of neuroendocrine tumors of the gastrointestinal tract. Review. Part 1

Πηγή: Clinical Endocrinology and Endocrine Surgery; No. 2 (2021); 60-72
Clinical Endocrinology and Endocrine Surgery; № 2 (2021); 60-72

Θεματικοί όροι: нейроэндокринные опухоли, желудочно-кишечный тракт, инсулинома, глюкагонома, нейроендокринні пухлини, шлунково-кишковий тракт, інсулінома, neuroendocrine tumors, gastrointestinal tract, insulinoma, glucagonoma, 3. Good health

Περιγραφή αρχείου: application/pdf

Σύνδεσμος πρόσβασης: http://jcees.endocenter.kiev.ua/article/view/235579

Predictive value of morphological features and proliferative markers (mitotic index, Ki-67, PHH3) in bronchopulmonary neuroendocrine tumors

Πηγή: Pathologia; Vol. 18 No. 3 (2021): Pathologia; 254-262
Патология; Том 18 № 3 (2021): Патология; 254-262
Патологія; Том 18 № 3 (2021): Патологія; 254-262

Θεματικοί όροι: нейроендокринні пухлини легень, метастазы, імуногістохімія, митотический индекс, necrosis, метастази, survival rates, показатели выживаемости, некроз, morphology, immunohistochemistry, Ki-67, морфологія, показники виживаності, PHH3, морфология, lung neuroendocrine tumor, mitotic index, мітотичний індекс, иммуногистохимия, metastases, нейроэндокринные опухоли лёгких

Περιγραφή αρχείου: application/pdf

Σύνδεσμος πρόσβασης: http://pat.zsmu.edu.ua/article/view/239530

NEUROENDOCRINE TUMORS OF THE CERVIX ; НЕЙРОЭНДОКРИННЫЕ ОПУХОЛИ ШЕЙКИ МАТКИ

Συγγραφείς: K. V. Safronova, A. S. Artemieva, A. O. Nuganen, G. F. Kutusheva, D. A. Chuglova, N. A. Mikaya, I. V. Berlev, A. F. Urmancheeva, A. M. Belyaev, E. A. Ulrich, К. В. Сафронова, А. С. Артемьева, А. О. Нюганен, Г. Ф. Кутушева, Д. А. Чуглова, Н. А. Микая, И. В. Берлев, А. Ф. Урманчеева, А. М. Беляев, Е. А. Ульрих

Πηγή: Siberian journal of oncology; Том 19, № 5 (2020); 97-107 ; Сибирский онкологический журнал; Том 19, № 5 (2020); 97-107 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2020-19-5

Θεματικοί όροι: шейка матки, neuroendocrine neoplasias, neuroendocrine tumors, cervix, нейроэндокринные неоплазии, нейроэндокринные опухоли

Περιγραφή αρχείου: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/1584/794; Tavassoli F.A., Devilee P. Pathology and genetics of tumors of the breast and female genital organs. WHO, IARC Press. Verh Dtsch Ges Pathol 2002; 86: 116–9.; Kurman R.J., Carcangiu M.L., Herrington C.S. WHO classification of tumours of the female reproductive organs. Lyon IARC Press, 2014. 540 p.; Ambros R.A., Park J.S., Shah K.V., Kurman R.J. Evaluation of histologic, morphometric, and immunohistochemical criteria in the differential diagnosis of small cell carcinomas of the cervix with particular reference to human papillomavirus types 16 and 18. Mod Pathol. 1991 Sep; 4(5): 586–93.; Gadducci A., Carinelli S., Aletti G. Neuroendrocrine tumors of the uterine cervix: A therapeutic challenge for gynecologic on- cologists. Gynecol Oncol. 2017 Mar; 144(3): 637–646. doi:10.1016/j.ygyno.2016.12.003.; Kim J.Y., Hong S.M., Ro J.Y. Recent updates on grading and classification of neuroendocrine tumors. Ann Diagn Pathol. 2017 Aug; 29: 11–16. doi:10.1016/j.anndiagpath.2017.04.005.; Guadagno E., De Rosa G., Del Basso De Caro M. Neuroendocrine tumours in rare sites: differences in nomenclature and diagnostics - a rare and ubiquitous histotype. J Clin Pathol. 2016 Jul; 69(7): 563–74. doi:10.1136/jclinpath-2015-203551.; Salvo G., Gonzalez Martin A., Gonzales N.R., Frumovitz M. Updates and management algorithm for neuroendocrine tumors of the uterine cervix. Int J Gynecol Cancer. 2019 Jul; 29(6): 986–995. doi:10.1136/ijgc-2019-000504.; Klimstra D.S., Modlin I.R., Coppola D., Lloyd R.V., Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010; 39(6): 707–12. doi:10.1097/MPA.0b013e3181ec124e.; Guadagno E., De Rosa G., Del Basso De Caro M. Neuroendocrine tumours in rare sites: differences in nomenclature and diagnostics-a rare and ubiquitous histotype. J Clin Pathol. 2016; 69(7): 563–74. doi:10.1136/jclinpath-2015-203551.; Travis W.D., Brambilla E., Burke A.P., Marx A., Nicholson A.G. Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. J Thorac Oncol. 2015 Sep; 10(9): 1240–1242. doi:10.1097/JTO.0000000000000663.; Chen J., Macdonald O.K., Gaffney D.K. Incidence, mortality, and prognostic factors of small cell carcinoma of the cervix. Obstet Gynecol. 2008 Jun; 111(6): 1394–402. doi:10.1097/AOG.0b013e318173570b.; Margolis B., Tergas A.I., Chen L., Hou J.Y., Burke W.M., Hu J.C., Ananth C.V., Neugut A.I., Hershman D.L., Wright J.D. Natural history and outcome of neuroendocrine carcinoma of the cervix. Gynecol Oncol. 2016 May; 141(2): 247–254. doi:10.1016/j.ygyno.2016.02.008.; Abeler V.M., Holm R., Nesland J.M., Kjørstad K.E. Small cell carcinoma of the cervix. A clinicopathologic study of 26 patients. Cancer. 1994; 73(3): 672–7. doi:10.1002/1097-0142(19940201)73:33.0.co;2-r.; Toki T., Katayama Y., Motoyama T. Small-cell neuroendocrine carcinoma of the uterine cervix associated with micro-invasive squamous cell carcinoma and adenocarcinoma in situ. Pathol Int. 1996 Jul; 46(7): 520–5. doi:10.1111/j.1440-1827.1996.tb03648.x.; Hara H., Ishii E., Hondo T., Nakagawa M., Teramoto K., Oyama T. Cytological features of atypical carcinoid combined with adenocarcinoma of the uterine cervix. Diagn Cytopathol. 2012 Aug; 40(8): 724–8. doi:10.1002/dc.21657. PMID: 21394936.; Muñoz N., Bosch F.X., de Sanjosé S., Herrero R., Castellsagué X., Shah K.V., Snijders P.J., Meijer C.J.; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003 Feb 6; 348(6): 518–27. doi:10.1056/NEJMoa021641.; de Sanjose S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., Tous S., Felix A., Bravo L.E., Shin H.R., Vallejos C.S., de Ruiz P.A., Lima M.A., Guimera N., Clavero O., Alejo M., LlombartBosch A., Cheng-Yang C., Tatti S.A., Kasamatsu E., Iljazovic E., Odida M., Prado R., Seoud M., Grce M., Usubutun A., Jain A., Suarez G.A., Lombardi L.E., Banjo A., Menéndez C., Domingo E.J., Velasco J., Nessa A., Chichareon S.C., Qiao Y.L., Lerma E., Garland S.M., Sasagawa T., Ferrera A., Hammouda D., Mariani L., Pelayo A., Steiner I., Oliva E., Meijer C.J., Al-Jassar W.F., Cruz E., Wright T.C., Puras A., Llave C.L., Tzardi M., Agorastos T., Garcia-Barriola V., Clavel C., Ordi J., Andújar M., Castellsagué X., Sánchez G.I., Nowakowski A.M., Bornstein J., Muñoz N., Bosch F.X.; Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11(11): 1048–56. doi:10.1016/S1470-2045(10)70230-8.; Alejo M., Alemany L., Clavero O., Quiros B., Vighi S., Seoud M., Cheng-Yang C., Garland S.M., Juanpere N., Lloreta J., Tous S., Klaustermeier J.E., Quint W., Bosch F.X., de Sanjosé S., Lloveras B.; RIS HPV TT study group. Contribution of Human papillomavirus in neuroendocrine tumors from a series of 10,575 invasive cervical cancer cases. Papillomavirus Res. 2018; 5: 134–142. doi:10.1016/j.pvr.2018.03.005.; Lai C.H., Chang C.J., Huang H.J., Hsueh S., Chao A., Yang J.E., Lin C.T., Huang S.L., Hong J.H., Chou H.H., Wu T.I., Huang K.G., Wang C.C., Chang T.C. Role of human papillomavirus genotype in prognosis of early-stage cervical cancer undergoing primary surgery. J Clin Oncol. 2007 Aug 20; 25(24): 3628–34. doi:10.1200/JCO.2007.11.2995.; Kasuga Y., Miyakoshi K., Nishio H., Akiba Y., Otani T., Fukutake M., Ikenoue S., Ochiai D., Matsumoto T., Tanaka K., Minegishi K., Kuji N., Roberts R., Aoki D., Tanaka M. Mid-trimester residual cervical length and the risk of preterm birth in pregnancies after abdominal radical trachelectomy: a retrospective analysis. BJOG. 2017; 124(11): 1729–1735. doi:10.1111/1471-0528.14688.; Castle P.E., Pierz A., Stoler M.H. A systematic review and metaanalysis on the attribution of human papillomavirus (HPV) in neuroendocrine cancers of the cervix. Gynecol Oncol. 2018; 148(2): 422–9. doi:10.1016/j.ygyno.2017.12.001.; Howitt B.E., Kelly P., McCluggage W.G. Pathology of Neuroendocrine Tumours of the Female Genital Tract. Curr Oncol Rep. 2017 Sep; 19(9): 59. doi:10.1007/s11912-017-0617-2.; Giorgadze T., Kanhere R., Pang C., Ganote C., Miller L.E., Tabaczka P., Brown E., Husain M. Small cell carcinoma of the cervix in liquid-based Pap test: utilization of split-sample immunocytochemical and molecular analysis. Diagn Cytopathol. 2012 Mar; 40(3): 214–9. doi:10.1002/dc.21542.; McCluggage W.G., Kennedy K., Busam K.J. An immunohistochemical study of cervical neuroendocrine carcinomas: Neoplasms that are commonly TTF1 positive and which may express CK20 and P63. Am J Surg Pathol. 2010 Apr; 34(4): 525–32. doi:10.1097/PAS.0b013e3181d1d457.; Houghton O., McCluggage W.G. The expression and diagnostic utility of p63 in the female genital tract. Adv Anat Pathol. 2009 Sep; 16(5): 316–21. doi:10.1097/PAP.0b013e3181b507c6.; Chan J.K., Tsui W.M., Tung S.Y., Ching R.C. Endocrine cell hyperplasia of the uterine cervix. A precursor of neuroendocrine carcinoma of the cervix? Am J Clin Pathol. 1989 Dec; 92(6): 825–30. doi:10.1093/ajcp/92.6.825.; Deng G.H., Zhang X., Wu L.Y. Clinicopathological analysis of nine cases of small cell carcinoma of the uterine cervix. Zhonghua Zhong Liu Za Zhi. 2010 Mar; 32(3): 199–202.; Albores-Saavedra J., Gersell D., Gilks C.B., Henson D.E., Lindberg G., Santiago H., Scully R.E., Silva E., Sobin L.H., Tavassoli F.J., Travis W.D., Woodruff J.M. Terminology of endocrine tumors of the uterine cervix: results of a workshop sponsored by the College of American Pathologists and the National Cancer Institute. Arch Pathol Lab Med. 1997 Jan; 121(1): 34–9.; Lojek M.A., Fer M.F., Kasselberg A.G., Glick A.D., Burnett L.S., Julian C.G., Greco F.A., Oldham R.K. Cushing’s syndrome with small cell carcinoma of the uterine cervix. Am J Med. 1980; 69(1): 140–4. doi:10.1016/0002-9343(80)90513-6.; Ishibashi-Ueda H., Imakita M., Yutani C., Ohmichi M., Chiba Y., Kubo T., Waki M. Small cell carcinoma of the uterine cervix with syndrome of inappropriate antidiuretic hormone secretion. Mod Pathol. 1996 Apr; 9(4): 397–400.; Koch C.A., Azumi N., Furlong M.A., Jha R.C., Kehoe T.E., Trowbridge C.H., O’Dorisio T.M., Chrousos G.P., Clement S.C. Carcinoid syndrome caused by an atypical carcinoid of the uterine cervix. J Clin Endocrinol Metab. 1999 Nov; 84(11): 4209–13. doi:10.1210/jcem.84.11.6126.; Boruta D.M.2nd, Schorge J.O., Duska L.A., Crum C.P., Castrillon D.H., Sheets E.E. Multimodality therapy in early-stage neuroendocrine carcinoma of the uterine cervix. Gynecol Oncol. 2001; 81(1): 82–7. doi:10.1006/gyno.2000.6118.; Wang H.L., Lu D.W. Detection of human papillomavirus DNA and expression of p16, Rb, and p53 proteins in small cell carcinomas of the uterine cervix. Am J Surg Pathol. 2004; 28(7): 901–8. doi:10.1097/00000478-200407000-00009.; Kuroda N., Wada Y., Inoue K., Ohara M., Mizuno K., Toi M., Tanaka A., Wani Y., Yanai H. Smear cytology findings of large cell neuroendocrine carcinoma of the uterine cervix. Diagn Cytopathol. 2013; 41(7): 636–9. doi:10.1002/dc.21834.; Dongol S., Tai Y., Shao Y., Jiang J., Kong B. A retrospective clinicopathological analysis of small-cell carcinoma of the uterine cervix. Mol Clin Oncol. 2014 Jan; 2(1): 71–75. doi:10.3892/mco.2013.193.; Hoskins P.J., Wong F., Swenerton K.D., Pike J.A., Manji M., McMurtrie E., Acker B., Le Riche J. Small cell carcinoma of the cervix treated with concurrent radiotherapy, cisplatin, and etoposide. Gynecol Oncol. 1995; 56(2): 218–25. doi:10.1006/gyno.1995.1035.; Hoskins P.J., Swenerton K.D., Pike J.A., Lim P., Aquino-Parsons C., Wong F., Lee N. Small-cell carcinoma of the cervix: fourteen years of experience at a single institution using a combined-modality regimen of involved-field irradiation and platinum-based combination chemotherapy. J Clin Oncol. 2003 Sep 15; 21(18): 3495–501. doi:10.1200/JCO.2003.01.501.; Chang T.C., Lai C.H., Tseng C.J., Hsueh S., Huang K.G., Chou H.H. Prognostic factors in surgically treated small cell cervical carcinoma followed by adjuvant chemotherapy. Cancer. 1998 Aug 15; 83(4): 712–8. doi:10.1002/(sici)1097-0142(19980815)83:43.0.co;2-v.; Viswanathan A.N., Deavers M.T., Jhingran A., Ramirez P.T., Levenback C., Eifel P.J. Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence. Gynecol Oncol. 2004 Apr; 93(1): 27–33. doi:10.1016/j.ygyno.2003.12.027.; Zivanovic O., Leitao M.M.Jr., Park K.J., Zhao H., Diaz J.P., Konner J., Alektiar K., Chi D.S., Abu-Rustum N.R., Aghajanian C. Small cell neuroendocrine carcinoma of the cervix: Analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy. Gynecol Oncol. 2009 Mar; 112(3): 590–3. doi:10.1016/j.ygyno.2008.11.010.; Chan J.K., Loizzi V., Burger R.A., Rutgers J., Monk B.J. Prognostic factors in neuroendocrine small cell cervical carcinoma: a multivariate analysis. Cancer. 2003; 97: 568–574.; Wang K.L., Chang T.C., Jung S.M., Chen C.H., Cheng Y.M., Wu H.H., Liou W.S., Hsu S.T., Ou Y.C., Yeh L.S., Lai H.C., Huang C.Y., Chen T.C., Chang C.J., Lai C.H. Primary treatment and prognostic factors of small cell neuroendocrine carcinoma of the uterine cervix: a Taiwanese Gynecologic Oncology Group study. Eur J Cancer. 2012; 48(10): 1484–94. doi:10.1016/j.ejca.2011.12.014.; Bermúdez A., Vighi S., García A., Sardi J. Neuroendocrine cervical carcinoma: a diagnostic and therapeutic challenge. Gynecol. Oncol. 2001; 82: 32–39.; Sheets E.E., Berman M.L., Hrountas C.K., Liao S.Y., DiSaia P.J. Surgically treated, early-stage neuroendocrine small-cell cervical carcinoma. Obstet Gynecol. 1988 Jan; 71(1): 10–14.; Nasu K., Hirakawa T., Okamoto M., Nishida M., Kiyoshima C., Matsumoto H., Takai N., Narahara H. Advanced small cell carcinoma of the uterine cervix treated by neoadjuvant chemotherapy with irinotecan and cisplatin followed by radical surgery. Rare Tumors. 2011 Mar 30; 3(1): e6. doi:10.4081/rt.2011.e6.; Krivak T.C, McBroom J.W., Sundborg M.J., Crothers B., Parker M.F. Large cell neuroendocrine cervical carcinoma: a report of two cases and review of the literature. Gynecol Oncol. 2001; 82(1): 187–91. doi:10.1006/gyno.2001.6254.; Gilks C.B., Young R.H., Gersell D.J., Clement P.B. Large cell neuroendocrine [corrected] carcinoma of the uterine cervix: a clinicopathologic study of 12 cases. Am J Surg Pathol. 1997 Aug; 21(8): 905–14. doi:10.1097/00000478-199708000-00004.; Sato Y., Shimamoto T., Amada S., Asada Y., Hayashi T. Large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathological study of six cases. Int J Gynecol Pathol. 2003 Jul; 22(3): 226–30. doi:10.1097/01.PGP.0000071046.12278.D1.; Embry J.R., Kelly M.G., Post M.D., Spillman M.A. Large cell neuroendocrine carcinoma of the cervix: prognostic factors and survival advantage with platinum chemotherapy. Gynecol Oncol. 2011 Mar; 120(3): 444–8. doi:10.1016/j.ygyno.2010.11.007.; Rhemtula H., Grayson W., van Iddekinge B., Tiltman A. Large-cell neuroendocrine carcinoma of the uterine cervix--a clinicopathological study of five cases. S Afr Med J. 2001 Jun; 91(6): 525–8.; Emerson R.E., Michael H., Wang M., Zhang S., Roth L.M., Cheng L. Cervical Carcinomas With Neuroendocrine Differentiation: A Report of 28 Cases With Immunohistochemical Analysis and Molecular Genetic Evidence of Common Clonal Origin With Coexisting Squamous and Adenocarcinomas. Int J Gynecol Pathol. 2016 Jul; 35(4): 372–84. doi:10.1097/PGP.0000000000000254.; Futagami M., Yokoyama Y., Mizunuma H. Presentation of a patient with pT2bN1M0 small cell carcinoma of the uterine cervix who obtained long-term survival with maintenance chemotherapy, and literature-based discussion. Eur J Gynaecol Oncol. 2011; 32(1): 99–102.; Yoseph B., Chi M., Truskinovsky A.M., Dudek A.Z. Large-cell neuroendocrine carcinoma of the cervix. Rare Tumors. 2012 Jan 2; 4(1): e18. doi:10.4081/rt.2012.e18.; https://www.siboncoj.ru/jour/article/view/1584

Διαθεσιμότητα: https://www.siboncoj.ru/jour/article/view/1584
https://doi.org/10.21294/1814-4861-2020-19-5-97-107

A new and simple on-line tool to differentiate neuroendocrine and solid pseudopapillary pancreatic tumors ; Новый и простой онлайн-инструмент для дифференциации нейроэндокринных и солидных псевдопапиллярных опухолей поджелудочной железы

Συγγραφείς: V. Yu. Chernina, I. A. Blokhin, D. I. Marapov, A. G. Kriger, D. V. Kalinin, W. Schima, G. G. Karmazanovsky, В. Ю. Чернина, И. А. Блохин, Д. И. Марапов, А. Г. Кригер, Д. В. Калинин, Вольфганг Шима, Г. Г. Кармазановский

Πηγή: Medical Visualization; Том 24, № 1 (2020); 13-28 ; Медицинская визуализация; Том 24, № 1 (2020); 13-28 ; 2408-9516 ; 1607-0763

Θεματικοί όροι: новообразования поджелудочной железы, pancreas, neuroendocrine tumors, pancreatic neoplasms, поджелудочная железа, нейроэндокринные опухоли

Περιγραφή αρχείου: application/pdf

Relation: https://medvis.vidar.ru/jour/article/view/850/584; https://medvis.vidar.ru/jour/article/view/850/585; Gordon-Dseagu V.L., Devesa S.S., Goggins M., Stolzenberg-Solomon R. Pancreatic cancer incidence trends: Evidence from the Surveillance, Epidemiology and End Results (SEER) population-based data. Int J Epidemiol 2017; 47.2: 427-439. https://doi.org/10.1093/ije/dyx232.; Papavramidis T., Papavramidis S. Solid Pseudopapillary Tumors of the Pancreas: Review of 718 Patients Reported in English Literature. J Am Coll Surg 2005; 200(6): 965-72. https://doi.org/10.1016/j.jamcollsurg.2005.02.011; Rindi G., Bordi C. Highlights of the biology of endocrine tumours of the gut and pancreas. Endocr Relat Cancer 2003; 10(4): 427-36. https://doi.org/10.1677/erc.0.0100427.; Massironi S., Sciola V., Peracchi M., Ciafardini C., Spampatti M.P., Conte D. Neuroendocrine tumors of the gastro-entero-pancreatic system. World J Gastroenterol 2008; 14: 5377–5384. https://doi.org/10.3748/wjg.14.5377.; Ehehalt F., Saeger H.D., Schmidt C.M. et al. Neuroendocrine Tumors of the Pancreas LEARNING OBJECTIVES. Oncologist 2009; 140014(5):456-467. https://doi.org/10.1634/theoncolo-gist.2008-0259.; Tang L.H., Untch B.R., Reidy D.L. et al. Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: A pathway distinct from poorly differentiated neuroendocrine carcinomas. Clin Cancer Res 2016; 22(4): 1011-1017. https://doi.org/10.1158/1078-0432.CCR-15-0548; Tang L.H., Basturk O., Sue J.J., Klimstra D.S. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas. Am J Surg Pathol 2016; 40(9): 1192-1202. https://doi.org/10.1097/PAS.0000000000000662.; Tang X., Zhang X., Che X., Chen Y., Wang C. Peripancreatic lymphadenopathy on preoperative radiologic images predicts malignancy in pancreatic solid pseudopapillary neoplasm. Int J Clin Exp Med 2015; 8(9): 16315-21. PMID: 26629150.; Choi J.Y., Kim M.J., Kim J.H. et al. Solid pseudopapillary tumor of the pancreas: typical and atypical manifestations. Am J Roentgenol 2006; 187(2): 178-86. https://doi.org/10.2214/AJR.05.0569.; Naar L., Spanomichou D.A., Mastoraki A., Smyrniotis V., Arkadopoulos N. Solid Pseudo-papillary Neoplasms of the Pancreas: A Surgical and Genetic Enigma. World J Surg 2017; 41(7): 1871-1881. https://doi.org/10.1007/s00268-017-3921-y.; Clancy T.E., Surgical Management of Pancreatic Neuroendocrine Tumors. Hematol Oncol Clin North Am 2016; 30(1): 103-18. https://doi.org/10.1016/j.hoc.2015.09.004.; Falconi M., Mantovani W., Crippa S., Mascetta G., Salvia R., Pederzoli P. Pancreatic insufficiency after different resections for benign tumours. Br J Surg 2008; 95(1): 85-91. https://doi.org/10.1002/bjs.5652.; Parekh J.R., Wang S.C., Bergsland E.K. et al. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients. Pancreas 2012; 41(6): 840-4. https://doi.org/10.1097/MPA.0b013e31823cdaa0.; Lee D.S., Jeffrey R.B., Kamaya A. Islet-cell tumors of the pancreas: spectrum of MDCT findings: a pictorial essay. Appl Radiol 2009; 38: 10–28.; Lewis R.B., Lattin G.E., Paal E. Pancreatic endocrine tumors: radiologic-clinicopathologic correlation. Radiographics 2010; 30(6): 1445-64. https://doi.org/10.1148/rg.306105523.; Lee N.J., Hruban R.H., Fishman E.K. Pancreatic neuroendocrine tumor: review of heterogeneous spectrum of CT appearance. Abdom Radiol 2018; 43: 3025-3034. https://doi.org/10.1007/s00261-018-1574-4.; Coleman K.M., Doherty M.C., Bigler S.A. Solid-pseudopapillary tumor of the pancreas. Radiographics. 2003; 23(6): 1644-8. https://doi.org/10.1148/rg.236035006.; Li D.L., Li H.S., Xu Y.K., Wang Q.S., Chen R.Y., Zhou F. Solid pseudopapillary tumor of the pancreas: clinical features and imaging findings. Clin Imaging 2018; 48: 113-121. https://doi.org/10.1016/j.clinimag.2017.10.006.; Canellas R., Lo G., Bhowmik S., Ferrone C., Sahani D. Pancreatic neuroendocrine tumor: Correlations between MRI features, tumor biology, and clinical outcome after surgery. J Magn Reson Imaging 2018; 47(2): 425-432. https://doi.org/10.1002/jmri.25756.; Kang C.M., Cho A., Kim H. et al. Clinical correlations with (18)FDG PET scan patterns in solid pseudopapillary tumors of the pancreas: still a surgical enigma? Pancreatology 2014;(6):515-23. https://doi.org/10.1016/j.pan.2014.08.003.; Matsumoto T., Okabe H., Yamashita YI. et al. Clinical role of fludeoxyglucose (18F) positron emission tomography/computed tomography ((18)F-FDG PET/CT) in patients with pancreatic neuroendocrine tumors. Surg Today 2019; 49(1): 21-26. https://doi.org/10.1007/s00595-018-1703-2.; Prasad V., Tiling N., Denecke T., Brenner W., Plöckinger U. Potential role of (68)Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease. Eur J Nucl Med Mol Imaging 2016; 43(11): 2014-20. https://doi.org/10.1007/s00259-016-3421-6.; Yu P.F., Hu ZH., Wang XB. et al. Solid pseudopapillary tumor of the pancreas: a review of 553 cases in Chinese literature. World J Gastroenterol 2010; 16(10): 1209-14. https://doi.org/10.3748/wjg.v16.i10.1209.; Zheng X., Tan X., Wu B. CT imaging features and their correlation with pathological findings of solid pseudopapillary tumor of pancreas. J Biomed Eng 2014; 31: 107-112.; Horiguchi S., Kato H., Shiraha H. Dynamic computed tomography is useful for prediction of pathological grade in pancreatic neuroendocrine neoplasm. J Gastroenterol Hepatol 2017; 32: 925-931. https://doi.org/10.1111/jgh.13594.; Kim D.W., Kim H.J., Kim K.W. et al. Neuroendocrine neoplasms of the pancreas at dynamic enhanced CT: comparison between grade 3 neuroendocrine carcinoma and grade 1/2 neuroendocrine tumour. Eur Radiol 2015; 25: 1375-1383. https://doi.org/10.1007/s00330-014-3532-z.; Choi T.W., Kim T.W., Yu M.N., Park S.J., Han J.K. Pancreatic neuroendocrine tumor: prediction of the tumor grade using CT findings and computerized texture analysis. Acta Radiol 2018; 59: 383-392. https://doi.org/10.1177/0284185117725367.; Rodallec M., Vilgrain V., Couvelard A., et al. Endocrine pancreatic tumours and helical CT: contrast enhancement is correlated with microvascular density, histoprognostic factors and survival. Pancreatology 2006; 6: 77-85. https://doi.org/10.1159/000090026.; d’Assignies G., Couvelard A., Bahrami S. et al. Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors. Radiology 2009; 250: 407-416. https://doi.org/10.1148/radiol.2501080291.; https://medvis.vidar.ru/jour/article/view/850

Διαθεσιμότητα: https://medvis.vidar.ru/jour/article/view/850
https://doi.org/10.24835/1607-0763-2020-1-13-28

Biochemical basics of imaging in positron emission tomography in oncology. Part 2 ; Биохимические основы визуализации при позитронной эмиссионной томографии в онкологии. Часть 2

Συγγραφείς: A. V. Leontyev, N. A. Rubtsova, A. I. Khalimon, G. F. Khamadeeva, M. T. Kuliev, I. V. Pylova, T. N. Lazutina, A. A. Kostin, A. D. Kaprin, А. В. Леонтьев, Н. А. Рубцова, А. И. Халимон, Г. Ф. Хамадеева, М. Т. Кулиев, И. В. Пылова, Т. Н. Лазутина, А. А. Костин, А. Д. Каприн

Πηγή: Medical Visualization; Том 24, № 1 (2020); 119-132 ; Медицинская визуализация; Том 24, № 1 (2020); 119-132 ; 2408-9516 ; 1607-0763

Θεματικοί όροι: EGFR, radiopharmaceuticals, receptor imaging, receptor ligands, RGD-peptides, NET, DOTA-conjugated peptides, DOTATATE, DOTATOC, DOTANOC, PSMA ligands, estrogen receptors imaging, FES, sex hormone imaging, радиофармпрепараты, РФП, рецепторная визуализация, лиганды к рецепторам, RGD-пептиды, нейроэндокринные опухоли, DOTA-пептиды, лиганды к ПСМА, лиганды к эстрогеновым рецепторам, ФЭС, лиганды к рецепторам половых гормонов

Περιγραφή αρχείου: application/pdf

Relation: https://medvis.vidar.ru/jour/article/view/895/595; Brooks P.C., Strömblad S., Sanders L.C., von Schalscha T.L., Aimes R.T., Stetler-Stevenson W.G., Quigley J.P., Cheresh D.A. Localization of matrix metalloproteinase; MMP-2 to the surface of invasive cells by interaction with integrin αvβ3. Cell. 1996; 85 (5): 683–693. https://doi.org/10.1016/s0092-8674(00)81235-0; Haubner R., Wester H.J., Reuning U., SenekowitschSchmidtke R., Diefenbach B., Kessler H., Stöcklin G., Schwaiger M. Radiolabeled αvβ3 Integrin Antagonists: A New Class of Tracers for Tumor Targeting. J. Nucl. Med. 1999; 40: 1061–1071.; Chen H., Niu G., Wu H., Chen X. Clinical application of radiolabeled RGD peptides for PET imaging of integrin αvβ3. Theranostics. 2016; 6 (1): 78–92. https://doi.org/10.7150/thno.13242; Karen A., Kurdziel M.D., Lindenberg L., Choyke P.L. Oncologic angiogenesis imaging in the clinic – how and why. Imaging Med. 2011; 3 (4): 445–457.; Haubner R., Wester H.J., Reuning U., SenekowitschSchmidtke R., Diefenbach B., Kessler H., Stöcklin G., Schwaiger M. Radiolabeled αvβ3 integrin antagonists: A new class of tracers for tumor targeting. J. Nucl. Med. 1999; 40 (6): 1061–1071.; Niu G., Chen X. RGD PET: From Lesion Detection to Therapy Response Monitoring. J. Nucl. Med. 2015; 57 (4): 501–502. https://doi.org/10.2967/jnumed.115.168278; Zhang H., Liu N., Gao S., Hu X., Zhao W., Tao R., Chen Z., Zheng J., Sun X., Xu L., Li W., Yu J., Yuan S. Can an 18F-AlF-NOTA-PRGD2 PET/CT scan predict the treatment sensitivity of concurrent chemoradiotherapy in patients with newly diagnosed glioblastoma? J. Nucl. Med. 2016; 57: 524–529. https://doi.org/10.2967/jnumed.115.165514; Cescato R., Schulz S., Waser B., Eltschinger V., Rivier J.E., Wester H.J., Culler M., Ginj M., Liu Q., Schonbrunn A., Reubi J.C. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J. Nucl. Med. 2006; 47 (3): 502–511. https://doi.org/10.1111/bph.12551; Sollini M., Erba P.A., Fraternali A. PET and PET/CT with 68Gallium-labeled somatostatin analogues in non GEPNETs tumors. Sci. Wld J. 2014; 2014: Article ID 194123. https://doi.org/10.1155/2014/194123; Hofland L.J., Lamberts S.W. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr. Rev. 2003; 24: 28–47. https://doi.org/10.1210/er.2000-0001; Virgolini I., Ambrosini V., Bomanji J.B., Baum R.P., Fanti S., Gabriel M., Papathanasiou N.D., Pepe G., Oyen W., De Cristoforo C., Chiti A. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur. J. Nucl. Med. Mol. Imaging. 2010; 37: 2004–2010. https://doi.org/10.1007/s00259-010-1512-3; Geijer H., Breimer L.H. Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur J. Nucl. Med. Mol. Imaging. 2013; 40 (11): 1770–1780. https://doi.org/10.1007/s00259-013-2482-z; Fani M., Nicolas G.P., Wild D. Somatostatin Receptor Antagonists for Imaging and Therapy. J. Nucl. Med. 2017; 58 (Suppl. 2): 61S–66S. https://doi.org/10.2967/jnumed.116.186783; Chan D.L.H., Pavlakis N., Schembri G.P., Bernard E.J., Hsiao E., Hayes A., Barnes T., Diakos C., Khasraw M., Samra J., Eslick E., Roach P.J., Clarke S.J., Bailey D.L. Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance. Theranostics. 2017; 7 (5): 1149–1158. https://doi.org/10.7150/thno.18068; Hindié E. The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors. Theranostics. 2017; 7 (5): 1159–1163. https://doi.org/10.7150/thno.19588; Fani M., Nicolas G.P., Wild D. Somatostatin receptor antagonists for imaging and therapy. J. Nucl. Med. 2017; 58: 61S–66S. https://doi.org/10.2967/jnumed.116.186783; Fani M., Peitl P.K., Velikyan I. Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms. Pharmaceuticals. 2017; 10 (1): 30. https://doi.org/10.3390/ph10010030; Ginj M., Zhang H., Waser B., Cescato R., Wild D., Wang X., Erchegyi J., Rivier J., Mäcke H.R., Reubi J.C. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proceedings of the National Academy of Sciences. 2006; 103 (44): 16436–16441. https://doi.org/10.1073/pnas.0607761103; Lenzo N., Cardaci J., Meyrick D., Henderson A., Crouch J., Yeo S., Turner H. Lu-177 OPS-201 (satareotide) Trial for Metastatic Neuroendocrine Tumour. Доступно по: http://theranostics.com.au/wp-content/uploads/2016/05/Lu-177-OPS-201-Satareotide-Trial-for-Metastatic-Neuroendocrine-Tumours.pdf. Ссылка активна на 01.07.2019г.; Rylova S.N., Stoykow C., Del Pozzo L., Abiraj K., Tamma M.L., Kiefer Y., Fani M., Maecke H.R. The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model. PLoS One. 2018; 13 (4): e0195802. https://doi.org/10.1371/journal.pone.0195802; Ginj M., Zhang H., Waser B., Cescato R., Wild D., Wang X., Erchegyi J., Rivier J.R. Mäcke H.R, Reubi J.C. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc. Natl. Acad. Sci. USA. 2006; 3 (44): 16436–16441. https://doi.org/10.1073/pnas.0607761103; Nicolas G.P., Schreiter N., Kaul F., Uiters J., Bouterfa H., Kaufmann J., Wild D. Sensitivity comparison of 68GaOPS202 and 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors: a prospec tive phase II imaging study. J. Nuclear Med. 2017; 59 (6): 915–921. https://doi.org/10.2967/jnumed.117.199760; Kunz P.L. Carcinoid and neuroendocrine tumors: building on success. J. Clin. Oncol. 2015; 33: 1855–1863. https://doi.org/10.1200/JCO.2014.60.2532; Эндокринология: Национальное руководство. Краткое издание / Под ред. И.И. Дедова, Г.А. Мельниченко. М.: ГЭОТАР-Медиа, 2013. 752 с.; Bozkurt M.F., Virgolini I., Balogova S., Beheshti M., Rubello D., Decristoforo C., Ambrosini V., Kjaer A., Delgado-Bolton R., Kunikowska J., Oyen W.J.G., Chiti A., Giammarile F., Sundin A., Fanti S. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTAconjugated somatostatin receptor targeting peptides and 18F-DOPA. Eur. J. Nucl. Med. Mol. Imaging. 2017; 44 (9): 1588–1601. https://doi.org/10.1007/s00259-017-3728-y; Khayum M.A., Doorduin J. Glaudemans A.W.J.M., Dierckx R.A.J.O. , E.F.J., de Vries R.A.J.O. PET and SPECT of Neurobiological Systems. Chapter 14. Berlin; Heidelberg: Springer-Verlag, 2014.; Liu C., Gong C., Liu S., Zhang Y., Zhang Y., Xu X., Yuan H., Wang B., Yang Z. 18F-FES PET/CT influences the staging and management of newly diagnosed Oestrogen Receptor positive Breast Cancer Patients: A Retrospective Comparative Study with 18F-FDG PET/CT. J. Nucl. Med. 2019; 60 (1): 596.; Sun Y., Yang Z., Zhang Y., Xue J., Wang M., Shi W., Zhu B., Hu S., Yao Z., Pan H., Zhang Y. The preliminary study of 16α-[18F]fluoroestradiol PET/CT in assisting the individualized treatment decisions of breast cancer patients. PLoS ONE. 2015; 10 (1): e0116341. https://doi.org/10.1371/journal.pone.0116341; Nienhuis H.H., van Kruchten M., Elias S.G., Glaudemans A.W.J.M., de Vries E.F.J., Bongaerts A.H.H., Schröder C.P., de Vries E.G.E., Hospers G.A.P. 18F-Fluoroestradiol Tumor Uptake Is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients. J. Nucl. Med. 2018; 59 (8): 1212–1218. https://doi.org/10.2967/jnumed.117.198846; Gong C., Yang Z., Sun Y., Zhang J., Zheng C., Wang L., Zhang Y., Xue J., Yao Z., Pan H., Wang B., Zhang Y. A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel. Scientific Reports. 2017; 7: 6584. https://doi.org/10.1038/s41598-017-06903-8; Mertan F.V., Lindenberg L., Choyke P.L., Turkbey B. PET imaging of recurrent and metastatic prostate cancer with novel tracers. Future Oncol. 2016; 12 (21): 2463–2477. https://doi.org/10.2217/fon-2016-0270; Horoszewicz J.S., Kawinski E., Murphy G.P. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987; C (7): 27–935.; Afshar-Oromieh A., Babich J.W., Giesel C.K.F.L., Eisenhut M., Kopka K., Haberkorn U. The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer. J Nucl Med. 2016;57:79S–89S. https://doi.org/10.2967/jnumed.115.170720; Giesel F.L., Kesch C., Yun M., Cardinale J., Haberkorn U., Kopka K., Kratochwil C., Hadaschik B.A. 18F-PSMA-1007 PET/CT detects micrometastases in a patient with biochemically recurrent prostate cancer. Clin. Genitourin Cancer. 2017; 15 (3): 497–499. https://doi.org/10.1016/j.clgc.2016.12.029; Леонтьев А.В., Рубцова Н.А., Халимон А.И., Кулиев М.Т., Пылова И.В., Лазутина Т.Н., Хамадеева Г.Ф., Алексеев Б.Я., Костин А.А., Каприн А.Д. Применение радиомеченых лигандов к простатспецифическому мембранному антигену для определения локализации био химического рецидива рака предстательной железы методом ПЭТ/КТ (обзор литературы). Медицинская визуализация. 2018; 22 (3): 81–97. https://doi.org/10.24835/1607-0763-2018-3-81-97.; Afshar-Oromieh A., Holland-Letz T., Giesel F.L., Kratochwil C., Mier W., Haufe S., Debus N., Eder M., Eisenhut M., Schäfer M., Neels O., Hohenfellner M., Kopka K., Kauczor H.U., Debus J., Haberkorn U. Diagnostic performance of (68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: Evaluation in 1007 patients. Eur. J. Nucl. Med. Mol. Imaging. 2017; 44 (8): 1258–1268. https://doi.org/10.1007/s00259-017-3711-7; Schwenck J., Rempp H., Reischl G., Kruck S., Stenzl A., Nikolaou K., Pfannenberg C., la Fougère C. Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. Eur. J. Nucl. Med. Mol. Imaging. 2017; 44 (1): 92–101. https://doi.org/10.1007/s00259-016-3490-6; Roach P.J., Francis R., Emmett L., Hsiao E., Kneebone A., Hruby G., Eade T., Nguyen Q.A., Thompson B.D., Cusick T., McCarthy M., Tang C., Ho B., Stricker P.D., Scott A.M. The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: Results of an Australian prospective multicenter study. J. Nucl. Med. 2018; 59 (1): 82–88. https://doi.org/10.2967/jnumed.117.197160; Albisinni S., Artigas C., Aoun F., Biaou I., Grosman J., Gil T., Hawaux E., Limani K., Otte F.X., Peltier A., Sideris S., Sirtaine N., Flamen P., van Velthoven R. Clinical impact of 68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: Preliminary analysis of a multidisciplinary approach. BJU Int. 2017; 120 (2): 197–203. https://doi.org/10.1111/bju.13739; Велиев Е.И., Томилов А.А., Богданов А.Б. Спасительная лимфаденэктомия у пациентов с подтвержденным ПЭТ/КТ олигометастатическим рецидивом рака предстательной железы. Онкоурология. 2018; 14 (4): 79–86. https://doi.org/10.17650/1726-9776-2018-14-4-79-86; Kabasakal L., Demirci E., Ocak M. et al. Evaluation of PSMA PET/CT imaging using a 68Ga- HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nucl. Med. Commun. 2015; C-36 (6): 582–587.; Giesel F.L., Knorr K., Spohn F. et al. Detection efficacy of [18F]PSMA-1007 PET/CT in 251 Patients with biochemical recurrence after radical prostatectomy. J. Nucl. Med. 2018; 60 (3): 362–368. https://doi.org/10.2967/jnumed.118.212233; Сакаева Д.Д., Гордиев М. Г. Рецептор эпидермального фактора роста как мишень молекулярно-направленной терапии у непредлеченых пациентов с немелкоклеточным раком легкого. Злокачественные опухоли. 2016; 3 (19). https://doi.org/10.18027/2224-5057-2016-3-54-59; Горбунова В.А., Артамонова Е.В., Бредер В.В., Лактионов К.К., Моисеенко Ф.В., Реутова Е.В. и др. Практические рекомендации по лекарственному лечению немелкоклеточного рака легкого. Злокачественные опухоли: Практические рекомендации RUSSCO; 3s2, 2017 (т. 7): с. 28–42.; Sun X., Xiao Z.,Chen G. et al. A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management. Sci Transl. Med. 2018: 7: 10 (431). https://doi.org/10.1126/scitranslmed.aan8840; https://medvis.vidar.ru/jour/article/view/895

Διαθεσιμότητα: https://medvis.vidar.ru/jour/article/view/895
https://doi.org/10.24835/1607-0763-2020-1-119-132

ВОЗМОЖНОСТИ МРТ С КОНТРАСТНЫМ УСИЛЕНИЕМ В ОЦЕНКЕ СТЕПЕНИ ДИФФЕРЕНЦИРОВКИ МЕТАСТАЗОВ НЕЙРОЭНДОКРИННЫХ ОПУХОЛЕЙ В ПЕЧЕНИ

Θεματικοί όροι: степень дифференцировки, нейроэндокринные опухоли (НЭО), МРТ с контрастным усилением, neuroendocrine tumors (NET), differentiation grade, MRI with contrast enhancement

A PILOT CLINICAL TRIAL TO MONITOR RESPONSE TO CHEMOTHERAPY USING THE CA-62 MARKER OF EPITHELIAL CARCINOMAS ; ПИЛОТНОЕ КЛИНИЧЕСКОЕ ИССЛЕДОВАНИЕ ПО МОНИТОРИНГУ ЭФФЕКТИВНОСТИ ХИМИОТЕРАПИИ ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ У ПАЦИЕНТОВ С ПОМОЩЬЮ МАРКЕРА ЭПИТЕЛИАЛЬНЫХ КАРЦИНОМ СА-62

Συγγραφείς: G. G. Khakimova, Zh. R. Cherkasova, S. A. Tsurkan, G. A. Fedchikov, N. V. Suganov, V. A. Gorbunova, Г. Г. Хакимова, Ж. Р. Черкасова, С. А. Цуркан, Г. А. Федчиков, Н. В. Суганов, В. А. Горбунова

Πηγή: Siberian journal of oncology; Том 18, № 5 (2019); 18-28 ; Сибирский онкологический журнал; Том 18, № 5 (2019); 18-28 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2019-18-5

Θεματικοί όροι: прогрессирование, gastric cancer, small-cell lung cancer, colorectal cancer, neuroendocrine cancer, ovarian cancer, СА-62 cancer antigen, immunochemiluminescent assay, cancer marker, monitoring, stable disease, disease progression, рак желудка, мелкоклеточный рак легкого, колоректальный рак, рак яичников, нейроэндокринные опухоли, раковый антиген СА-62, иммунохемилюминесцентный анализ, онкомаркер, мониторинг, стабилизация

Περιγραφή αρχείου: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/1184/663; Jackson S.E., Chester J.D. Personalised cancer medicine. Int J Cancer. 2015 Jul 15; 137(2): 262–6. doi:10.1002/ijc.28940.; Mascaux C., Tomasini P., Greiller I., Barilsi F. Personalised medicine for nonsmall cell lung cancer. Eur Respir Rev. 2017 Nov 15; 26(146). pii: 170066. doi:10.1183/16000617.0066-2017.; Baxendale S., van Eedan F., Wilkinson R. The power of Zebrafish in Personalised Medicine. Adv Exp Med Biol. 2017; 1007: 179–197. doi:10.1007/978-3-319-60733-7_10.; Ballman K.V. Biomarker: Predictive or Prognostic? J Clin Oncol. 2015 Nov 20; 33(33): 3968–71. doi:10.1200/JCO.2015.63.3651.; Huang J., Hu W., Sood A.K. Prognostic Biomarkers in Ovarian Cancer. Cancer Biomark. 2010–2011; 8(0): 231–251. doi:10.3233/CBM2011-0212.; Weigel M.T., Dowsett M. Current and emerging biomarkers in breast cancer: prognostic and predictive. Endocr Relat Cancer. 2010 Sep 23; 17(4): R245–62. doi:10.1677/ERC-10-0136.; Das V., Kalita J., Pal M. Predictive and prognostic biomarkers in colorectal cancer: a systematic review of recent advances and challenges. Biomed Pharmacother. 2017 Mar; 87: 8–19. doi:10.1016/j.biopha.2016.12.064.; Rodriguez-Vida A., Strijbos M., Hutson T. Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma. ESMO Open. 2016 May 25; 1(3): e000013. doi:10.1136/esmoopen-2015-000013.; Ledermann J.A., Raja F.A., Fotopoulou C., Gonzalez-Martin A., Colombo N., Sessa C.; ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct; 24 Suppl 6: vi24–32. doi:10.1093/annonc/mdt333.; Parker C., Gillessen S., Heidenreich A., Horwich A.; ESMO Guidelines Committee. ESMO clinical guidelines for diagnosis, treatment and follow-up for prostate cancer. Ann Oncol. 2015 Sep; 26 Suppl 5: v69–77. doi:10.1093/annonc/mdv222.; Minimum clinical recommendations ESMO [Internet]. URL: https://www.jastro.or.jp/customer/guideline/2016/10/esmo_index.pdf (cited 10.01.2019).; Семёнова А.И. Мониторинг эффективности лечения и выявление рецидивов с помощью биомаркеров. Практическая онкология. 2011; 12(4): 171–177.; Moro R., Tcherkassova J., Song E., Shen G., Moro R., Schmid R., Hu X., Kummer A., Chen C. A new broad-spectrum cancer marker. In-Vitro Diagnostic Technology. 2005; 1–6.; Moro R., Gulyaeva-Tcherkassova J., Stieber P. Icreased AFPReceptor (RECAF) values in the serum of patients with early stages of breast cancer. J Curr Oncol. 2012; 19(1): e1–8. doi:10.3747/co.19.979.; Tcherkassova J., Abramovich C., Moro R., Chen C., Smit R., Gerber A., Moro R. Combination of CA125 and RECAF biomarkers for early detection of Ovarian cancer. Tumor Biol. 2011; 32(4): 831–838. doi:10.1007/s13277-011-0186-1.; Moro R., Uriel J. Early localization of AFP in the developing nervous system of the chicken. Oncodevelop Biol Med. 1981; 2: 391–398.; Villacampa M.J., Moro R., Naval J., Failly-Crepin C. Lampreave F., Uriel J. RECAFs in a human breast cancer cell line. Biochem Biophys Res Commun. 1984; 122: 1322–1327. doi:10.1016/0006-291X(84)91236-1.; Jacobson H.I., Bennett J.A., Mizejewski G.J. Inhibition of estrogendependent breast cancer growth by a reaction product of alpha-fetoprotein and estradiol. Cancer Res. 1990; 50(2): 415–420.; Mizejewski G.J., Phillips L., Stoll W. In vitro studies of the abortogenic potential of anti-serum to alpha-fetoprotein. Int J Immunopharmacol. 1981; 3(1): 87–95.; Moro R., Tamaoki T., Wegmann T.G., Longenecker B.M., Laderoute M.P. Monoclonal antibodies directed against a widespread oncofetal antigen: the alpha-feloprotein receptor. Tumour Biol. 1993; 14(2): 116–30. doi:10.1159/000217864.; Laderoute M. A new perspective on the nature of the cancer problem: anticellular senescence. Mol Carcinog. 1994 Jul; 10(3): 125–33.; Uriel J., Villacampa M.J., Moro R., Naval l., Failly-Crepin C. Uptake of radiolabeled alpha•fetoprolein by mouse mammary carcinomas and its usefulness in tumor scintigraphy. Cancer Res. 1984; 44: 5314–5319.; Pepe M.S., Etzioni R., Feng Z., Potter J.D., Thompson M.L., Thornquist M., Winget M., Yasui Y. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001 Jul 18; 93(14): 1054–61. doi:10.1093/jnci/93.14.1054.; Uriel J., Poupon M.F., Geuskens M. Alphafoecoprolein uptake by cloned cell lines derived from a nickel•induced rat rhabdomyosarcoma. J Cancer. 1983; 48: 261–269.; Suzuki Y., Zeng C.Q., Alpert E. Isolation and partial characterization of a specific alpha-fetoprotein receptor on human monocytes. Clin Invest. 1992; 90: 1530–6. doi:10.1172/JCI116021.; Torres J.M., Darracq N., Uriel J. Membrane proteins from Lymphoblastoid cells showing cross-affinity for alpha-fetoprotein and albumin. Isolation and characterization. Biochim Biophys Acta. 1992 Sep 4; 1159(1): 60–6.; Kanevsky V.Yu., Pozdnyakova L.P., Aksenova O.A., Severin S.E., Katukov V.Yu., Severin E.S. Isolation and characterization of AFP binding proteins from tumor and fetal human tissues. Biochem Mol Biol Int. 1997; 41(6): 1143–51.; Черешнев В.А., Родионов С.Ю., Васильев Н.В., Орлов О.А., Черкасов В.А. Иммунотерапия злокачественных опухолей альфафетопротеином человека как этап комбинированного и комплексного лечения онкологических больных [Интернет]. URL: http://www.a-fp.ru/articles/immunoterapiya-zlokachestvennyh-opuholey-alfa-fetoproteinomcheloveka-kak-etap (дата обращения: 10.01.2019).; Tcherkassova J., Tsurkan S., Smirnova G., Borisova J., Moro R., Treshalina H. Binding characterization of the targetingdrug AIMPILA to AFP receptors in human tumor xenografts. Tumour Biol. 2017 Oct; 39(10): 1010428317734815. doi:10.1177/1010428317734815.; Ohkawa K., Tsukada Y., Abe T., Takada K., Hibi N. Overcoming effect of antibody against rat alpha-fetoprotein (AFP) on the growth of daunorubicin-resistant mutant rat ascites hepatoma cell line AH66. Int J Cancer. 1989; 44(3): 489–493. doi:10.1002/ijc.2910440319.; Астахов Д.В., Коваленко Н.А., Сологуб В.К., Большакова Т.Д., Северин С.Е., Шатверян Г.А., Гудовский Л.М. Определение антител к рецептору альфа-фетопротеина у онкологических больных. Вопросы биологической, медицинской и фармакологической химии. 1999; 2: 27–30.; Molina R., Auge J.M., Escudero J.M., Marrades R., Viñolas N., Carcereny E., Ramirez J., Filella X. Mucins CA 125, CA 19-9, CA 15.3, and TAG 72.3 as tumor markers in patinets with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE. Tumour Biol. 2008; 29(6): 371–80. doi:10.1159/000181180.; Molina R., Augé J.M., Bosch X., Escudero J.M., Viñolas N., Marrades R., Ramírez J., Carcereny E., Filella X. Usefulness of serum tumor markers, including progastrin-releasing peptide in patients with lung cancer. Correlation and histology. Tumour Biol. 2009; 30(3): 121–9. doi:10.1159/000224628.; European Group on Tumor markers. Consensus recommendations. Anticancer Res. 1999, 19: 2785–820.; Iwanicki-Caron I., Di Fiore F., Roque I., Astruc E., Stetiu M., Duclos A., Tougeron D., Saillard S., Thureau S., Benichou J., Paillot B., Basuyau J.P., Michel P. Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer. J Clin Oncol. 2008 Aug 1; 26(22): 3681–6. doi:10.1200/JCO.2007.15.0904.; Li C.S., Cheng B.C., Ge W., Gao J.F. Clinical value of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 assay in the elderly patients with pleural effusions. nt J Clin Pract. 2007 Mar; 61(3): 444–8. doi:10.1111/j.17421241.2006.01111.x.; Prados M.C., Alvarez-Sala R., Blasco R., Chivato T., García Satué J.L., García Río F.J., Gómez de Terrero F.J. Villamor The clinical value of neuron-specific enolase as a tumor marker in bronchoalveolar lavage. Cancer. 1994 Sep 1; 74(5): 1552–5. doi:10.1002/1097-0142(19940901)74:53.0.co;2-f.; Karnak D., Beder S., Kayacan O., Ibis E., Oflaz G. Neuron-specific enolase and lung cancer. Am J Clin Oncol. 2005 Dec; 28(6): 586–90.; Saba M.A., Valeh T., Ehteram H., Haddad Kashani H., Ghazi Zahedi M. Diagnostic Value of Neuron-Specific Enolase (NSE) and Cancer Antigen 15-3 (CA 15-3) in the Diagnosis of Pleural Effusions. Asian Pac J Cancer Prev. 2017 Jan 1; 18(1): 257–261. doi:10.22034/APJCP.2017.18.1.257.; Jørgensen L.G., Osterlind K., Genollá J., Gomm S.A., Hernández J.R., Johnson P.W., Løber J., Splinter T.A., Szturmowicz M. Serum neuron-specific enolase (S-NSE) and the prognosis in small cell lung cancer (SCLC): a combined multivariable analysis on data from nine centers. Br. J. Cancer 1996; 74; 463–467. doi:10.1038/bjc.1996.383.; Carney D.N., Teeling M. Neuron-specific enolase: how useful as a cancer marker? Eur J Cancer Clin Oncol. 1988 May; 24(5): 825–8.; https://www.siboncoj.ru/jour/article/view/1184

Διαθεσιμότητα: https://www.siboncoj.ru/jour/article/view/1184
https://doi.org/10.21294/1814-4861-2019-18-5-18-28